The LEADER CV outcomes trial showed Victoza® was proven to reduce CV risk2
Mechanism of Action
The Victoza® mechanism of action works in multiple systems
Victoza® slows gastric emptying and the rate at which glucose enters the blood after meals.
Victoza® helps lower hepatic glucose output by suppressing pancreatic glucagon secretion.
Victoza® stimulates beta cells to release insulin when blood glucose is high.
- Internal calculations based on IMS MIDAS database, April 2017.
- Marso SP, Daniels GH, Brown-Frandsen K, et al; the LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322.